Takeda Pharmaceutical Co. Ltd. said it has signed a deal to license Zinfandel Pharmaceuticals Inc.’s technology as a way to one day target and potentially treat Alzheimer’s disease with Takeda’s diabetes pill Actos. Get the full story »
Inside these posts: Actos
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
FDA looks into diabetes drug, bladder cancer
The Food and Drug Administration said Friday that it has started a safety review of Takeda Pharmaceutical Co.’s diabetes drug Actos looking at links to bladder cancer.
The FDA said the review was prompted from preliminary, five-year data from an ongoing study involving the drug. The study, designed to follow patients for 10-years, is being funded by Takeda. Get the full story »
July 13, 2010 at 12:22 p.m.
Comments Off
Filed under: Scientists debate fate of Avandia
FDA scientists debated how to interpret the outcome of a large clinical trial that GlaxoSmithKline PLC says backs the safety of its diabetes drug Avandia.
Avandia is currently being reviewed by a federal panel that is scheduled to vote Wednesday on whether it thinks Avandia should remain on the U.S. market. FDA Commissioner Margaret Hamburg opened the meeting Tuesday, telling advisers to “follow the science where ever it may lead and the rest will fall into place.” Get the full story »
